2013-002259-14: The LIXI trial is aiming to recruit individuals with type 1 diabetes who are using insulin to control their disease. The trial is investigating whether a daily injection of a newly-licenced drug called lixisenatide, taken alongside a person\'s usual insulin medication can improve blood sugar levels after meals. |
|
|
| Ongoing | 2 | 33 | Europe | Lixisenatide 10 micrograms, Lixisenatide 20 micrograms, N/A, Lyxumia, Lyxumia | University of Oxford, Aventis Pharma Limited (Sanofi) | Type 1 diabetes mellitus | | | | |
